Arrowhead Pharmaceuticals (ARWR) Other Gross PP&E Adjustments (2016 - 2025)
Arrowhead Pharmaceuticals (ARWR) has disclosed Other Gross PP&E Adjustments for 16 consecutive years, with $420.1 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Other Gross PP&E Adjustments rose 3.85% year-over-year to $420.1 million, compared with a TTM value of $420.1 million through Dec 2025, up 3.85%, and an annual FY2025 reading of $416.8 million, up 5.05% over the prior year.
- Other Gross PP&E Adjustments was $420.1 million for Q4 2025 at Arrowhead Pharmaceuticals, up from $416.8 million in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at $420.1 million in Q4 2025 and bottomed at $19.9 million in Q3 2022.
- Average Other Gross PP&E Adjustments over 5 years is $201.8 million, with a median of $87.0 million recorded in 2022.
- The sharpest move saw Other Gross PP&E Adjustments crashed 61.97% in 2022, then soared 620.14% in 2024.
- Year by year, Other Gross PP&E Adjustments stood at $28.9 million in 2021, then skyrocketed by 62.15% to $46.8 million in 2022, then surged by 607.18% to $331.3 million in 2023, then rose by 22.1% to $404.5 million in 2024, then rose by 3.85% to $420.1 million in 2025.
- Business Quant data shows Other Gross PP&E Adjustments for ARWR at $420.1 million in Q4 2025, $416.8 million in Q3 2025, and $410.9 million in Q2 2025.